Planning law revolution: new opportunities for life science businesses
The life sciences industry is cautiously welcoming news of an overhaul in planning law in England and Wales that promises to ease the path to increasingly flexible and more nimble operations, write Lauren Fendick, Partner, and Clare Harman Clark, Senior Professional Support Lawyer, Taylor Wessing
Breaking News
Vetter wins in five categories at 2021 CMO Leadership Awards
Vetter was also the recipient of the award in a variety of categories in previous years
Pharmako achieves approval with Australian regulators
The Therapeutic Goods Administration is Australia’s equivalent regulating body to the FDA
European Commission purchases additional Moderna vaccine doses
Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to ...
Overcoming the challenge of accurate supplier labelling
Mergers and acquisitions are all too common for pharmaceutical manufacturers. And although the combination of two ...
ValiRx and Physiomics update collaboration agreement
The agreement supersedes a previous agreement between the two companies from 2011
Salipro Biotech awarded European Patent for DirectMX
The direct extraction of membrane proteins and library generation method is aimed at expediting drug development
Traceability: the backbone of the pharmaceutical supply chain
The pharmaceutical industry is one in which speed and quality are essential ingredients to a successful business. The ...
Avacta announces initial results of rapid antigen test
The company will now progress to a clinical validation with a larger number of patient samples to CE mark the test for ...
Stevanato Group contributes to ISPE container traceability paper
Being able to trace each container within manufacturing operations reduces risk and enables a detailed root cause ...
EU MDR changes are only the beginning: ensure IFU compliance now and be prepared for more
Despite the EU MDR being delayed until May 2021, some organisations are still burning valuable time in terms of ...
Technology to transform the capture and processing of drug safety data
The ultimate goal of pharmacovigilance is to prevent adverse drug reactions, thus maximising the benefit:risk ratio for ...
Why we need ISO 35001 for COVID testing ... and more besides
With virus testing at the centre of many COVID strategies, the ISO standard for managing biorisk has arrived at just ...
Europital warns clinical deficits may slow biotech development
Europital launched earlier this year as a science-focused CRO, and its SAB has therapeutic experience in oncology
Recipharm bolsters biologics offering
The license applies to the company’s Wasserburg, Germany facility
In Brief
Most Popular in Regulatory
Featured Companies
Reports
